^
Association details:
| Biomarker: | NRAS mutation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients
Excerpt:
...Efficacy of adoptive T cell therapy associated to intravenous injections of Nivolumab`Duration of the clinical response`Progression-free survival`Overall survival`Specific immune monitoring n°1: Evaluate the fraction of TIL specific to Melan-A and MELOE-1`Specific immune monitoring n°2: Evaluate the proportion of regulatory T cells`Specific immune monitoring n°3: Analyse the expression of tumor antigens`Specific immune monitoring n°4: Analyse the expression of immunosuppressive cytokines`Specific immune monitoring n°5: Analyse the expression of indoleamine 2,3-dioxygenase (IDO)`Specific immune monitoring n°6: Analyse the expression of FoxP3`Specific immune monitoring n°7: Analyse the expression of regulatory molecules`Specific immune monitoring n°8: Analyse the mutations of BRAF`Specific immune monitoring n°9: Analyse the mutations of Neuroblastoma Ras viral oncogene homolog (NRAS)`Specific immune monitoring n°10: Analyse the mutations of proto-oncogene ckit (cKit)`Specific immune monitoring n°11: Determine the percentage of reactive T cells in the expanded cells`Specific immune monitoring n°12: Determine the phenotype of the expanded T cells`Specific immune monitoring n°13: Test TIL reactivity...
Trial ID:
Source:
Title:
A Single-Arm, Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Treatment Containing an Anti-CTLA4 Monoclonal Antibody (CheckMate 172)
Excerpt:
...- Prior treatment with chemotherapy, interferon (adjuvant setting), Interleukin (IL-2), BRAF/MEK inhibitors for subjects with known BRAF mutations, Mitogen-activated or extracellular signal- regulated protein kinase (MEK) inhibitors for Neuroblastoma Ras Viral (v-ras) oncogene homolog (NRAS) mutations, and cKIT inhibitor subjects with known cKIT mutations are allowed...
Trial ID:
Less C2 evidence
Source:
Title:
Disease Recurrence during Adjuvant Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma: Clinical, Laboratory, and Radiological Characteristics in Patients from a Single Tertiary Referral Center
Published date:
09/14/2022
Excerpt:
CONTRADICTING EVIDENCE: Thus, we retrospectively analyzed the case records of all patients who commenced adjuvant ICI therapy...Seven of those patients were treated with nivolumab, and five were treated with pembrolizumab. All patients had cutaneous melanoma....Interestingly, patients with NRAS mutations were disproportionately represented (60%) in the patients who developed disease recurrence, suggesting that these patients should be closely monitored during adjuvant therapy.
DOI:
10.3390/ijms231810723
Source:
Title:
Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy
Excerpt:
Better objective response rates were associated with metachronous metastases (P = 0.04), PD-L1 tumour- and/or immune-cell status (P = 0.01), CD163+ histiocytes at advancing edges (P = 0.009) of primary melanomas and NRAS mutation (P = 0.019)....Pembrolizumab was given to 72.9% of the patients and nivolumab to 27.1%.
DOI:
10.1038/s41416-018-0168-9
